Wave Life Sciences is trading 5.11% down at $5.76 after analysts reduced 2026 revenue expectations to $52 million from $59 million.
- Disappointing second-quarter results included $2.3 million in revenue versus a $7.65 million estimate and an adjusted loss of $0.34 per share.
- The Delaware redomiciliation completed on August 10, 2026; management expects no material operational impact.